MaxCyte, Inc. Inducement Grants Under Nasdaq Listing Rule 5635 (5031I)
April 19 2022 - 2:01AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5031I
MaxCyte, Inc.
19 April 2022
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
GAITHERSBURG, MD, April 19, 2022 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT, MXCN), a leading commercial cell-engineering company
focused on providing enabling platform technologies to advance
innovative cell-based research as well as next-generation cell
therapeutic discovery, development and commercialization, today
announced that, on April 11, 2022, the Compensation Committee of
MaxCyte's Board of Directors granted stock options to purchase (i)
an aggregate of 54,000 shares of MaxCyte's common stock to four (4)
newly hired employees and (ii) 500,000 shares of MaxCyte's common
stock to Cenk Sumen, MaxCyte's newly hired Chief Scientific
Officer. Each of the foregoing stock options were granted as
material inducements to employment with MaxCyte in accordance with
Nasdaq Listing Rule 5635(c)(4) and were granted under the MaxCyte,
Inc. 2021 Inducement Plan (the "2021 Inducement Plan").
The stock options have a ten-year term and an exercise price of
$5.670per share, which is equal to the closing price of MaxCyte's
common stock on April 11, 2022. Each option will vest over a
four-year period, with 25% of the shares vesting after 12 months
and the remaining shares vesting monthly over the following 36
months, subject to the employee's continued employment with MaxCyte
on such vesting dates. The options are subject to the terms and
conditions of the 2021 Inducement Plan and the terms and conditions
of an award agreement covering the grants.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUWARRUVUSAUR
(END) Dow Jones Newswires
April 19, 2022 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2023 to Aug 2024